Gastrointestinal Adverse Events and Weight Reduction in People With Type 2 Diabetes Treated With Tirzepatide
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials
Diabetes Obes Metab 2023 Oct 18;[EPub Ahead of Print], H Patel, K Khunti, HW Rodbard, HS Bajaj, R Bray, Z Kindracki, Á RodríguezFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.